The analysis of efficacy and safety of thalidomide in inflammatory bowel disease

doi:10.3877/cma.j.issn.2095-3224.2017.03.013

Abstract

Abstract:

Thalidomide has received widespread attention as a cheap drug which has properties of anti-inflammatory, immunosuppression and immunomodulatory. This article elaborates the efficacy and safety of thalidomide in inflammatory bowel disease, and finds it possible mechanism. With the deepening of the research, thalidomide can be used as a salvage therapy when inflammatory bowel disease cannot induce and maintain remissions by glucocorticoid, immunosuppressive agents, biologic agents and so on.

Key words: Inflammatory bowel disease, Thalidomide, Effectiveness, Safety

Dan Mu, Yueyue Li, Yanqing Li. The analysis of efficacy and safety of thalidomide in inflammatory bowel disease[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(03): 234-237.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.03.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I03/234

References 24

[1]	Walsh A, Mabee J, Trivedi K. Inflammatory bowel disease [J]. Prim Care, 2011, 38 (3):415-432.
[2]	Vindigni SM, Zisman TL, Suskind DL.et al. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions [J]. Therap Adv Gastroenterol, 2016, 9(4):606-625.
[3]	罗涵青, 钱家鸣.沙利度胺在顽固性炎症性肠病中的应用 [J]. 中华内科杂志, 2012, 51(11):905-906.
[4]	Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies ininflammatory bowel disease: systematic review and meta-analysis [J]. Am J Gastroenterol, 2011, 106(4): 644-659.
[5]	Wettstein AR, Meagher AP.Thalidomide in Crohn′s disease [J]. Lancet, 1997, 350(9088):1445-1446.
[6]	Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn′s disease [J]. Gastroenterology, 1999, 117(6):1278-1287.
[7]	Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn′s disease: an open-label trial [J]. Gastroenterology, 1999, 117(6):1271-1277.
[8]	Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumor necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn′s disease [J]. Gut, 2002, 50(2):196-200.
[9]	Gerich ME, Yoon1 GL, Targan SR, et al. Long-term outcomes of thalidomide in refractory Crohn′s disease [J]. Aliment Pharmacol Ther, 2015, 41(5): 429-437.
[10]	Simon M, Pariente B, Lambert J, et al. Long-term Outcomes of Thalidomide Therapy for Adults with Refractory Crohn′s Disease [J]. Clinl Gastroenterol Hepatol, 2015, 14(7):966-972.
[11]	Diamanti A, Capriati T, Papadatou B, et al. The clinical implications of thalidomide in inflammatory bowel diseases [J]. Expert Rev Clin Immunol, 2015, 11(6):699-708.
[12]	Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results [J]. J Ped Gastroenterol Nutr, 2001, 32(2):178-181.
[13]	Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results [J]. Aliment Pharmacol Ther, 2007, 25(4): 419-427.
[14]	Lazzerini M, Marteloss i S, Magazzu G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial [J]. JAMA, 2013, 310(20):2164-2173.
[15]	Lazzerini M, Martelossi S, Cont G, et al. Orofacial granulomatosis in children: Think about Crohn′s disease [J]. Dig Liver Dis, 2015, 47(4); 338–341.
[16]	Waters MFR, Laing ABG, Ambikapathy A, et al. Treatment of ulcerative colitis with thalidomide [J]. Br Med J, 1979, 1(6166):792.
[17]	Lazzerini M, Martelossi S, Magazzu G, et al. Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial [J]. Inflamm Bowel Dis, 2015, 21(8):1739-1749.
[18]	Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes [J]. J Exp Med, 1991, 173(3):699–703.
[19]	Felipez LM, Gokhale R, Tierney MP, et al. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab [J]. J Pediatr Gastroenterol Nutr, 2012, 54(1):28-33.
[20]	Rafiee P, Stein DJ, Nelson VM, et al. Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelialcells (HIMEC) [J]. Am J Physiol Gastrointest Liver Physiol, 2010, 298(2):G167–176.
[21]	Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-Kb activity by thalidomide through suppression of IkB kinase activity [J]. J Biol Chem, 2001, 276(25): 22382–22387.
[22]	Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications [J]. Expert Opin Drug Saf, 2004, 3(1):47-56.
[23]	Cavalletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study [J]. Neurology, 2004, 62(12):2291-2293.
[24]	Ruemmele FM, Veres G, Kolho KL, et al.Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn′s disease [J]. J Crohns Colitis, 2014, 8(10):1179-1207.

Please choose a citation manager

Content to export